All In Biotech

Drug Trial Radar · NCT01515423

Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia

Last checked: Nov 19, 2026Latest source record: May 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,429 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,429

Actual

Start

May 2012

Primary completion

Feb 2015

Study completion Mar 2015

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 24, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate that a paliperidone palmitate 3 month formulation (PP3M) is as effective as the paliperidone palmitate 1 month formulation (PP1M) in the treatment of patients with schizophrenia who have been stabilized on PP1M.

Conditions

  • Schizophrenia

Interventions

  • PP3M 175 mg eq.Drug

    Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every third month for 48 weeks.

  • PP3M 263 mg eq.Drug

    Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every third month for 48 weeks.

  • PP3M 350 mg eq.Drug

    Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every third month for 48 weeks.

  • PP3M 525 mg eq.Drug

    Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every third month for 48 weeks.

  • Placebo (20% Intralipid)Drug

    Form= injection, route= intramuscular use. One injection monthly when not receiving active medication for 48 weeks.

  • PP1M 50 mg eq.Drug

    Type= exact number, unit= mg eq., number= 50, form= injection, route= intramuscular use. One injection every month for 48 weeks.

  • PP1M 75 mg eq.Drug

    Type= exact number, unit= mg eq., number= 75, form= injection, route= intramuscular use. One injection every month for 48 weeks.

  • PP1M 100 mg eq.Drug

    Type= exact number, unit= mg eq., number= 100, form= injection, route= intramuscular use. One injection every month for 48 weeks.

  • PP1M 150 mg eq.Drug

    Type= exact number, unit= mg eq., number= 150, form= injection, route= intramuscular use. One injection every month for 48 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Without Relapse at Week 48 During the Double-Blind PhaseTime frame: Up to 48 weeks

Locations

174 sites in 26 countries. Site status is shown where the registry gives one.

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Glendale, California

  • Site not named

    Long Beach, California

  • Site not named

    Oakland, California

  • Site not named

    Oceanside, California

  • Site not named

    Orange, California

  • Site not named

    San Diego, California

  • Site not named

    New Britain, Connecticut

  • Site not named

    Bradenton, Florida

  • Site not named

    Kissimmee, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Wichita, Kansas

  • Site not named

    East Lansing, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Jamaica, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Canton, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Memphis, Tennessee

  • Site not named

    Austin, Texas

  • Site not named

    Bothell, Washington

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Rosario, Argentina

  • Site not named

    Elizabeth Vale, Australia

  • Site not named

    Frankston, Australia

  • Site not named

    Innsbruck, Austria

  • Site not named

    Assebroek, Belgium

  • Site not named

    Bertrix, Belgium

  • Site not named

    Dave, Belgium

  • Site not named

    Heusden, Belgium

  • Site not named

    Jette, Belgium

  • Site not named

    Marchienne-au-Pont, Belgium

  • Site not named

    Sint-Denijs-Westrem, Belgium

  • Site not named

    Rio de Janeiro, Brazil

  • Site not named

    Burgas, Bulgaria

  • Site not named

    Kazanlak, Bulgaria

Showing 40 of 174 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.